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Abstract
Aims: To determine the normal value ranges of procalcitonin
(PCT) in women with uncomplicated pregnancies.
Methods: This prospective cohort study was conducted
between May 2009 and February 2010 among 60 women
without signs of clinical infection (31 vaginal deliveries, 29
cesarean sections) attending the maternity unit of the Uni-
versity of Geneva Hospitals. Sequential follow-up of PCT
levels was performed at 24–28 weeks (ns7), 36–40 weeks
(ns60), at delivery (ns59), and at days 2–3 (ns58) and
10 (ns53) postpartum using a sensitive PCT assay with a
functional sensitivity of 0.06 mg/L.
Results: Median levels of PCT were: 24–28 weeks: 0.043
mg/L (range 0.010–0.080); 36–40 weeks: 0.061 mg/L (range
0.010–0.110); at delivery: 0.068 mg/L (range 0.010–0.170);
days 2–3: 0.200 mg/L (range 0.030–5.00); and day 10: 0.060
mg/L (range 0.020–0.120). At days 2–3 postpartum, three
women had a PCT level between 0.25 mg/L and 0.5 mg/L
and two women had a level higher than 0.5 mg/L.
Conclusions: This study provides reference values for PCT
during the third trimester, at delivery and at the immediate
*Condensation: This study gives reference values of procalcitonin
during the third trimester, at delivery and the immediate postpartum
period in pregnant women without clinical infection.
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postpartum period. A cut-off PCT level of 0.25 mg/L can be
used during the third trimester, at delivery, and at the imme-
diate postpartum period to rule out infection.
Keywords: Delivery; normal values range; postpartum;
pregnancy; procalcitonin.
Introduction
Early detection of infection is of the utmost importance in
obstetrics and failure to diagnose it can lead to severe com-
plications for the mother, the fetus, and the newborn w16x.
However, infection during pregnancy is not reliably predict-
ed by commonly used laboratory tests, such as white cell
counts (WBC), neutrophil count or vaginal bacterial culture
w19x. Indeed, a physiologic increase in WBC exists during
uncomplicated pregnancy and the threshold to diagnose an
infection has to be modified during pregnancy w5x. In addi-
tion, clinical signs, such as fever and fetomaternal tachycar-
dia usually appear late w8x. C-reactive protein (CRP) is a
biological blood marker frequently used as a predictor of
intraamniotic infections (IAI), w19, 8x but a recent meta-anal-
ysis has shown that there is no evidence to support its use
for the early diagnosis of IAI w23x. Therefore, an accurate
and rapid marker for the diagnosis of early infection in the
context of pregnancy complications, such as preterm labor
or the premature rupture of membranes, is urgently needed.
Procalcitonin (PCT), a prohormone consisting of 116 ami-
no acids, is a normal precursor of the active hormone cal-
citonin and was first described in 1990 as a sepsis-induced
protein w1x. PCT levels are elevated in severe bacterial infec-
tions, but remain low in viral infections and non-specific
inflammatory disease w1, 10x. In healthy individuals, the nor-
mal PCT level is lower than 0.2 ng/mL w9x. Values increase
rapidly in pathologic conditions, leading to systemic inflam-
matory response syndrome (SIRS), w15x and a cut-off level
of 0.25 mg/L has been recently suggested for considering the
use of antibiotic treatment w15x.
Contradictory results have been reported in the few studies
that have measured PCT levels during pregnancy w2, 20–22x.
Therefore, there is a need to better define normal PCT values
in pregnant women before using PCT levels as a tool in the
management of infectious complications during the perinatal
period.
The objective of this study was to determine the normal
value ranges of PCT during the third trimester, at delivery,
and during postpartum in pregnant women without clinical
infection.
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Patient population
The study was conducted at the Department of Gynecology and
Obstetrics of the University Hospitals of Geneva, Geneva, Switzer-
land, a tertiary care hospital with approximately 4000 deliveries per
year. The study protocol was approved by the institutional Ethics
Committee and written informed consent was obtained from each
participant. We included women with singleton pregnancies, older
than 18 years, gestational age G24 weeks, and able to consent dur-
ing the prenatal consultation. Exclusion criteria were fever
(G388C), preterm labor, symptomatic urinary infection, preterm
rupture of membranes, preeclampsia and hemolysis, elevated liver
enzymes, and low platelet count (HELLP) syndrome. Blood samples
were taken at five time-points: 24–28 weeks, 36–40 weeks, delivery
(after placental delivery), and at days 2–3 (D2–3) and day 10 post-
partum (D10). We collected data on age, gestational age, parity,
smoking status, previous medical history, labor/delivery, postpartum
complications and neonatal outcome.
Laboratory test
PCT was measured using a rapid sensitive assay (Kryptor PCT,
BRAHMS, Hennigsdorf, Germany) based on a sandwich-typed
immunometric test with a lower detection level of 0.02 mg/L (func-
tional sensitivity, 0.06 mg/L). Inter-assay and intra-assay variations
are as follows: for 0.1 mg/L, 15% for both; for 0.2 mg/L, 6% and
10%, respectively, and for levels above 0.3 mg/L, -6% and 5%,
respectively (data from our laboratory and BRAHMS).
Statistical analysis
Data are expressed as medians, interquartile ranges, extreme values
and box-plots for each time-period considered. PCT levels between
sampling periods and according to mode of delivery (vaginal vs.
cesarean section) were compared using the paired Wilcoxon and
Mann-Whitney U-tests, respectively. Calculations were performed
with EpiInfo (Centers for Disease Prevention and Control, Atlanta,
GA, USA) and SPSS version 17 (SPSS Inc., Chicago, IL, USA);
graphs were drawn using R 2.10.1 (R project). We calculated the
specificity of the threshold of 0.25 mg/L to rule out infection as this
PCT value is commonly used in clinical practice to manage infec-
tious complications.
Results
From May 2009 to February 2010, 60 pregnant women were
included and followed prospectively. In group 1 (vaginal
delivery group), we included 31 women (28 spontaneous
vaginal deliveries and three instrumental deliveries). In group
2 (cesarean section wC-sectionx), we included 29 women (26
elective and three emergency). In order to have two homo-
geneous groups regarding the mode of delivery, we included
21 women at 35–36 weeks gestation when the indication for
delivery by C-section was established. The main character-
istics of study participants according to the mode of delivery
are presented in Table 1. Only maternal age at delivery was
different between the C-section group and the vaginal deliv-
ery group (Ps0.001). Four women (two in each group) had
a history of urinary infection prior to pregnancy, and two
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Figure 1 Evolution of procalcitonin levels at the end of pregnancy
(24–28 weeks, 36–40 weeks), immediately after delivery and in the
postpartum period (days 2–3 and day 10). The boxes represent 50%
of the values, the horizontal bar inside the median, and the lower
and upper bars the 10th and 90th percentiles, respectively.
(one per group) of chronic hypertension. Three women were
HIV seropositive (one in the vaginal group and two in the
C-section group).
During pregnancy, one woman in each group received pre-
emptive antibiotic treatment after inclusion for recurrent
asymptomatic bacteriuria. Their PCT levels were low w0.06
(vaginal) and 0.07 mg/L (C-section) at 24–28 weeksx. One
woman had a spontaneous preterm vaginal delivery and
developed clinical choriamnionitis during labor (fever 388C,
WBC 27.5 g/L, and high CRP 13 mg/L). Her PCT values at
delivery (0.17 mg/L) and at D3 postpartum (0.51 mg/L) were
excluded from the analysis. Eleven women in group 1
received antibiotic treatment during labor (nine for preven-
tion of group B streptococcus neonatal sepsis, one for endo-
carditis prophylaxis, and the woman with clinical
chorioamnionitis). In group 2, all women received antibiotic
prophylaxis (1st generation cephalosporin) after umbilical
cord clamping.
PCT levels from all 60 women at each sampling period
are shown in Figure 1. Median levels for each time period
were as follows: 24–28 weeks: 0.043 mg/L (range 0.010–
0.080); 36–40 weeks: 0.061 mg/L (range 0.010–0.110); at
delivery: 0.068 mg/L (range 0.010–0.170); D2–3: 0.200 mg/L
(range 0.030–5.00); and D10: 0.060 mg/L (range 0.020–
0.120). PCT levels significantly increased in the third tri-
mester of pregnancy and between delivery and D3 postpar-
tum. At D3, five of 57 women (8.8%) had values G0.25
mg/L (0.25, 0.31, 0.35, 0.56 and 5.00, respectively (Table 2)
without signs of infection during delivery and postpartum.
Using this threshold, the specificity of PCT levels at D3 post-
partum was 91.1% (exact 95% CI, 80.4; 97.0). The woman
with a D3 PCT level of 5.0 mg/L had received antibiotic
treatment during delivery (PCT value at delivery, 0.07
mg/L) for endocarditis prophylaxis and the following day
received an epidural blood patch for a lumbar puncture. Her
PCT returned to normal at D10 (0.12 mg/L). During the other
time periods, the specificity of the threshold of 0.25 mg/L
was 100% as no women had a PCT value G0.25 mg/L.
The evolution of PCT levels according to the mode of
delivery are shown in Table 2 and Figure 2. The increase of
PCT levels between 24–28 weeks and 36–40 weeks was not
statistically significant in the C-section group and was prob-
ably due to the low number of women sampled at
24–28 weeks. In contrast, the elevated levels between deliv-
ery and D3 was only significant in the group of women
delivering by C-section. At D10, PCT levels significantly
decreased among both groups, but they were significantly
higher in group 2 compared with group 1.
Comment
PCT is a promising biomarker of infection and ubiquitously
expressed in response to bacterial endotoxins and cytokines
w15x. In the present study, we established normal PCT levels
for the third trimester of pregnancy, at delivery, and the
immediate postpartum period in women without acute infec-
tion delivering vaginally or by C-section.
Our study demonstrates that PCT levels increase signifi-
cantly at the end of pregnancy and between delivery and D3
postpartum, with a decrease at D10 postpartum. PCT levels
are higher at D3 postpartum than at any other time-point and
this elevation is also associated with the mode of delivery,
being more marked after C-section. Labor and delivery stim-
ulates the inflammatory cascade and this can probably
explain the slight elevation of PCT levels at D3 w12x. Pre-
vious studies have shown that PCT concentrations rise after
abdominal surgery through the liberation of endotoxins with-
out bacterial translocation w13, 3x and this possibly accounts
for the more pronounced elevation among women delivering
by C-section.
Regardless of the PCT increase observed in our study,
PCT levels at the end of pregnancy, at delivery, and during
the postpartum period are within the same levels observed
in other non-infected adult populations w9, 15x. Our results
are in agreement with those of Assumma et al. who also
found very low levels of PCT at delivery (geometric mean,
0.01 mg/L), but using a different PCT assay than the one
used in our study w12x. In contrast, Torbe´ et al. found very
high PCT values during the second half of pregnancy (mean,
1.06 mg/L) w21x and at delivery (medium PCT value,
0.71 mg/L), thus precluding the use of PCT in the manage-
ment of infectious complications during pregnancy w20x.
We have assessed the specificity of the cut-off level of
0.25 mg/L to rule out infection as this value is currently used
to diagnose systemic infections and to guide the use of anti-
biotics in infected adult populations w4, 9, 17x. In our study,
this value has a specificity of 91.1% at D3 postpartum and
of 100% at the other four time-periods as all women had
PCT levels below this threshold. This is in agreement with
other studies showing specificities ranging from 78–96%
w10, 11, 14, 18x. Causes for ‘‘false-positive’’ PCT values
()0.25 mg/L), such as severe or surgical trauma, have been
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Table 2 Evolution of PCT levels (median and ranges) at the end of pregnancy and in the postpartum according to the mode of delivery.
Vaginal delivery (ns31) Cesarean section (ns29) P-value
n* Range Median Women (n) n* Range Median Women (n)
with values with values
)0.25 mg/L )0.25 mg/L
At 24–28 weeks 29 0.01–0.07 0.04 0 8** 0.03–0.08 0.05 0 0.14
At 36–40 weeks 31 0.01–0.11 0.06 0 29 0.03–0.10 0.07 0 0.05
At delivery 29 0.01–0.15 0.07 0 29 0.02–0.11 0.07 0 0.40
At day 2–3 28 0.03–5.00 0.07 2 29 0.05–0.56 0.10 3 -0.01
At day 10 27 0.02–0.12 0.05 0 26 0.03–0.10 0.07 0 -0.01
*Two samples at 24–28 weeks, one during labor, two at D2–3 and seven at D10 were missed.
**Twenty-one women were included at 35–36 weeks of gestation when the indication for cesarean section was established. No sampling
at 24–28 weeks.
Figure 2 (A, B) Evolution of procalcitonin levels at the end of pregnancy (24–28 weeks, 36–40 weeks), immediately after delivery and
in the postpartum period (days 2–3 and day 10) according to mode of delivery.
identified in other studies w7x. In our study, an example of
‘‘false-positive’’ was the woman who had 5.0 mg/L at D3
postpartum following an epidural blood patch for a lumbar
puncture, which is probably explained by an inflammatory
non-septic state.
A limitation of this study is that we did not collect data
on women with infectious complications and cannot assess
the sensitivity of the test. One woman had clinical chorioam-
niotitis and her PCT values (0.17 mg/L at delivery and
0.51 mg/L at D3) were excluded from the analysis. Never-
theless, those values were high, thus confirming the hypoth-
esis that PCT might be used for the diagnosis of infectious
complications during pregnancy. Further studies, including
case-control studies, are necessary to validate these data.
Additionally, further analyses should be conducted to eval-
uate the efficacy of PCT in guiding the duration of antibiotic
treatment in pregnant women.
Conclusion
In conclusion, our study provides normal PCT levels for the
third trimester of pregnancy, at delivery, and the immediate
postpartum period. PCT values are generally low, but with a
slight increase at D3 postpartum, especially among women
delivering by C-section. The PCT level of 0.25 mg/L can be
used to rule out infection during the perinatal period. How-
ever, additional studies should be conducted to assess the
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usefulness of PCT measurements in pregnant women with
suspected infection.
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